Profile data is unavailable for this security.
About the company
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
- Revenue in USD (TTM)225.00k
- Net income in USD-15.44m
- Incorporated2008
- Employees16.00
- LocationIbio Inc8800 HSC PkwyBRYAN 77807United StatesUSA
- Phone+1 (979) 446-0027
- Fax+1 (302) 636-5454
- Websitehttps://www.ibioinc.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NanoViricides Inc | 0.00 | -8.29m | 20.84m | 7.00 | -- | 1.63 | -- | -- | -0.698 | -0.698 | 0.00 | 0.8722 | 0.00 | -- | -- | 0.00 | -55.81 | -43.88 | -59.61 | -46.26 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.43 | -- | 16.23 | -- |
Pieris Pharmaceuticals Inc | 20.87m | -23.82m | 21.18m | 46.00 | -- | 1.13 | -- | 1.01 | -19.12 | -19.12 | 16.67 | 14.17 | 0.3707 | -- | 17.13 | 453,739.10 | -42.31 | -28.41 | -66.27 | -39.69 | -- | -- | -114.11 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
Iterum Therapeutics PLC | 0.00 | -28.34m | 21.75m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.658 | 0.00 | -- | -- | 0.00 | -86.93 | -118.12 | -150.76 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 2.06 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
Neurobo Pharmaceuticals Inc | 0.00 | -25.90m | 22.49m | 8.00 | -- | 1.15 | -- | -- | -4.97 | -4.97 | 0.00 | 2.30 | 0.00 | -- | -- | 0.00 | -89.41 | -95.57 | -117.09 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
Ibio Inc | 225.00k | -15.44m | 22.89m | 16.00 | -- | 1.07 | -- | 101.74 | -7.74 | -10.98 | 0.0586 | 2.47 | 0.0064 | -- | 0.4907 | 14,062.50 | -44.16 | -27.69 | -69.38 | -33.13 | -- | -- | -6,863.56 | -1,862.11 | -- | -- | 0.0689 | -- | -- | -35.52 | 47.31 | -- | -26.66 | -- |
Aligos Therapeutics Inc | 7.97m | -75.74m | 23.40m | 68.00 | -- | 0.6842 | -- | 2.94 | -25.99 | -25.99 | 1.89 | 10.70 | 0.0741 | -- | -- | 120,712.10 | -70.47 | -51.20 | -92.27 | -59.73 | -- | -- | -950.61 | -1,399.21 | -- | -- | 0.0031 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
Marker Therapeutics Inc | 3.73m | -10.31m | 23.47m | 8.00 | -- | 2.41 | -- | 6.30 | -1.16 | -1.17 | 0.4196 | 1.09 | 0.2217 | -- | 1.76 | 465,930.00 | -61.30 | -53.74 | -71.74 | -62.25 | -- | -- | -276.53 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
Gritstone bio Inc | 14.61m | -133.03m | 23.70m | 231.00 | -- | 1.07 | -- | 1.62 | -1.35 | -1.35 | 0.1391 | 0.1884 | 0.08 | -- | 49.20 | 63,251.08 | -72.86 | -48.08 | -83.37 | -55.18 | -- | -- | -910.50 | -573.71 | -- | -97.11 | 0.6461 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
Neurosense Therapeutics Ltd | 0.00 | -7.51m | 23.75m | 16.00 | -- | -- | -- | -- | -0.4392 | -0.4392 | 0.00 | -0.0943 | 0.00 | -- | -- | 0.00 | -154.72 | -- | -470.03 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.10 | -- | -- | -- |
RenovoRx Inc | 0.00 | -8.11m | 23.97m | 8.00 | -- | 2.58 | -- | -- | -0.6059 | -0.6059 | 0.00 | 0.3868 | 0.00 | -- | -- | 0.00 | -88.58 | -- | -106.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
Bolt Biotherapeutics Inc | 11.17m | -66.17m | 24.53m | 100.00 | -- | 0.2857 | -- | 2.20 | -1.74 | -1.74 | 0.2938 | 2.24 | 0.0709 | -- | -- | 111,660.00 | -42.03 | -48.32 | -47.37 | -54.03 | -- | -- | -592.57 | -2,267.00 | -- | -- | 0.00 | -- | 37.48 | -- | 21.45 | -- | -6.61 | -- |
Correlate Energy Corp | 5.65m | -34.51m | 24.57m | 19.00 | -- | -- | -- | 4.35 | -0.8359 | -0.8359 | 0.1457 | -0.0461 | 1.50 | -- | 11.12 | 297,377.40 | -915.61 | -315.47 | -- | -- | -6.45 | 15.42 | -610.79 | -201.03 | -- | -1.07 | -- | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
SAB Biotherapeutics Inc | 2.78m | -40.32m | 24.64m | 57.00 | -- | 0.5343 | -- | 8.86 | -5.69 | -5.69 | 0.3646 | 5.00 | 0.0571 | -- | 9.44 | 48,773.51 | -82.85 | -- | -102.37 | -- | -- | -- | -1,450.32 | -- | -- | -- | 0.0817 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
Nuo Therapeutics Inc | 1.03m | -2.69m | 24.74m | -- | -- | 40.34 | -- | 24.06 | -0.0622 | -0.0622 | 0.0237 | 0.0132 | 0.7332 | 0.954 | 4.06 | -- | -191.94 | -116.16 | -381.40 | -354.84 | 79.48 | 70.02 | -261.78 | -854.53 | 1.39 | -2,383.08 | 0.00 | -- | 442.12 | -14.99 | 0.0095 | -- | -- | -- |
Lisata Therapeutics Inc | 0.00 | -21.07m | 24.88m | 25.00 | -- | 0.6505 | -- | -- | -2.56 | -2.56 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -40.16 | -45.97 | -43.61 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Adar1 Capital Management LLCas of 05 Apr 2024 | 789.29k | 9.15% |
Opaleye Management, Inc.as of 01 Apr 2024 | 650.00k | 7.54% |
Lynx1 Capital Management LPas of 31 Mar 2024 | 600.00k | 6.96% |
Ikarian Capital LLCas of 31 Mar 2024 | 600.00k | 6.96% |
Armistice Capital LLCas of 31 Mar 2024 | 350.88k | 4.07% |
Geode Capital Management LLCas of 30 Jun 2024 | 49.20k | 0.57% |
Sabby Management LLCas of 31 Mar 2024 | 14.00k | 0.16% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 5.82k | 0.07% |
Tower Research Capital LLCas of 31 Mar 2024 | 5.60k | 0.07% |
UBS Securities LLCas of 31 Mar 2024 | 1.88k | 0.02% |